A prospective study on glioblastoma in the elderly

Alba A. Brandes, Francesca Vastola, Umberto Basso, Franco Berti, Giampietro Pinna, Antonino Rotilio, Marina Gardiman, Renato Scienza, Silvio Monfardini, Mario Ermani

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

BACKGROUND. Elderly patients (age > 65 years) with glioblastoma multiforme frequently are excluded from clinical studies, and prospective trials for patients with this age group do not exist to date. METHODS. The authors conducted a prospective trial in 79 consecutive elderly patients with glioblastoma who underwent surgery and received radiotherapy (59.44 grays in 33 fractions; Group A; n = 24 patients) or received the same radiotherapy plus adjuvant chemotherapy with procarbizine, lomustine, and vincristine (PCV; lomustine 110 mg/m2 on Day 1, procarbazine 60 mg/m2 on Days 8-21, and vincristine 1.4 mg/m2 on Days 8 and 29 every 42 days; Group B; n = 32 patients), or received the same radiotherapy plus adjuvant temozolomide (150 mg/m2 for 5 days every 28 days; Group C; n = 22 patients). RESULTS. The median time to disease progression (TTP) and median survival MST were 7.2 months (95% confidence interval [95%CI], 6.34-8.64) and 12.5 months (95%CI, 11.6-14.8), respectively. The TTP was significantly better for Group C compared with Groups A and B (10.7 months vs. 5.3 months and 6.9 months, respectively; P = 0.0002). Karnofsky performance status (KPS) (P <0.001) and temozolomide (P <0.001) were the only independent prognostic factors. Overall survival was better in Group C compared with Group A (14.9 months vs. 11.2 months; P = 0.002), but there were no statistical differences found between Groups A and B or between Groups B and C. Only KPS (P <0.001) was predictive of overall survival, even if temozolomide chemotherapy was very close to the significance level (P = 0.058). Hematologic Grade 3-4 toxicity was higher with the PCV chemotherapy regimen compared with the temozolomide chemotherapy regimen. CONCLUSIONS. Age alone should not preclude appropriate treatment in elderly patients with good performance status, for whom definitive radiation therapy and adjuvant chemotherapy with temozolomide is advised.

Original languageEnglish
Pages (from-to)657-662
Number of pages6
JournalCancer
Volume97
Issue number3
DOIs
Publication statusPublished - Feb 1 2003

Fingerprint

temozolomide
Glioblastoma
Prospective Studies
Lomustine
Karnofsky Performance Status
Radiotherapy
Vincristine
Adjuvant Chemotherapy
Drug Therapy
Survival
Disease Progression
Confidence Intervals
Procarbazine
Adjuvant Radiotherapy
Age Groups

Keywords

  • Chemotherapy
  • Elderly
  • Glioblastoma
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brandes, A. A., Vastola, F., Basso, U., Berti, F., Pinna, G., Rotilio, A., ... Ermani, M. (2003). A prospective study on glioblastoma in the elderly. Cancer, 97(3), 657-662. https://doi.org/10.1002/cncr.11097

A prospective study on glioblastoma in the elderly. / Brandes, Alba A.; Vastola, Francesca; Basso, Umberto; Berti, Franco; Pinna, Giampietro; Rotilio, Antonino; Gardiman, Marina; Scienza, Renato; Monfardini, Silvio; Ermani, Mario.

In: Cancer, Vol. 97, No. 3, 01.02.2003, p. 657-662.

Research output: Contribution to journalArticle

Brandes, AA, Vastola, F, Basso, U, Berti, F, Pinna, G, Rotilio, A, Gardiman, M, Scienza, R, Monfardini, S & Ermani, M 2003, 'A prospective study on glioblastoma in the elderly', Cancer, vol. 97, no. 3, pp. 657-662. https://doi.org/10.1002/cncr.11097
Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A et al. A prospective study on glioblastoma in the elderly. Cancer. 2003 Feb 1;97(3):657-662. https://doi.org/10.1002/cncr.11097
Brandes, Alba A. ; Vastola, Francesca ; Basso, Umberto ; Berti, Franco ; Pinna, Giampietro ; Rotilio, Antonino ; Gardiman, Marina ; Scienza, Renato ; Monfardini, Silvio ; Ermani, Mario. / A prospective study on glioblastoma in the elderly. In: Cancer. 2003 ; Vol. 97, No. 3. pp. 657-662.
@article{9cd12c3d46de4e45907bcaecb6bf9d34,
title = "A prospective study on glioblastoma in the elderly",
abstract = "BACKGROUND. Elderly patients (age > 65 years) with glioblastoma multiforme frequently are excluded from clinical studies, and prospective trials for patients with this age group do not exist to date. METHODS. The authors conducted a prospective trial in 79 consecutive elderly patients with glioblastoma who underwent surgery and received radiotherapy (59.44 grays in 33 fractions; Group A; n = 24 patients) or received the same radiotherapy plus adjuvant chemotherapy with procarbizine, lomustine, and vincristine (PCV; lomustine 110 mg/m2 on Day 1, procarbazine 60 mg/m2 on Days 8-21, and vincristine 1.4 mg/m2 on Days 8 and 29 every 42 days; Group B; n = 32 patients), or received the same radiotherapy plus adjuvant temozolomide (150 mg/m2 for 5 days every 28 days; Group C; n = 22 patients). RESULTS. The median time to disease progression (TTP) and median survival MST were 7.2 months (95{\%} confidence interval [95{\%}CI], 6.34-8.64) and 12.5 months (95{\%}CI, 11.6-14.8), respectively. The TTP was significantly better for Group C compared with Groups A and B (10.7 months vs. 5.3 months and 6.9 months, respectively; P = 0.0002). Karnofsky performance status (KPS) (P <0.001) and temozolomide (P <0.001) were the only independent prognostic factors. Overall survival was better in Group C compared with Group A (14.9 months vs. 11.2 months; P = 0.002), but there were no statistical differences found between Groups A and B or between Groups B and C. Only KPS (P <0.001) was predictive of overall survival, even if temozolomide chemotherapy was very close to the significance level (P = 0.058). Hematologic Grade 3-4 toxicity was higher with the PCV chemotherapy regimen compared with the temozolomide chemotherapy regimen. CONCLUSIONS. Age alone should not preclude appropriate treatment in elderly patients with good performance status, for whom definitive radiation therapy and adjuvant chemotherapy with temozolomide is advised.",
keywords = "Chemotherapy, Elderly, Glioblastoma, Radiotherapy, Temozolomide",
author = "Brandes, {Alba A.} and Francesca Vastola and Umberto Basso and Franco Berti and Giampietro Pinna and Antonino Rotilio and Marina Gardiman and Renato Scienza and Silvio Monfardini and Mario Ermani",
year = "2003",
month = "2",
day = "1",
doi = "10.1002/cncr.11097",
language = "English",
volume = "97",
pages = "657--662",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - A prospective study on glioblastoma in the elderly

AU - Brandes, Alba A.

AU - Vastola, Francesca

AU - Basso, Umberto

AU - Berti, Franco

AU - Pinna, Giampietro

AU - Rotilio, Antonino

AU - Gardiman, Marina

AU - Scienza, Renato

AU - Monfardini, Silvio

AU - Ermani, Mario

PY - 2003/2/1

Y1 - 2003/2/1

N2 - BACKGROUND. Elderly patients (age > 65 years) with glioblastoma multiforme frequently are excluded from clinical studies, and prospective trials for patients with this age group do not exist to date. METHODS. The authors conducted a prospective trial in 79 consecutive elderly patients with glioblastoma who underwent surgery and received radiotherapy (59.44 grays in 33 fractions; Group A; n = 24 patients) or received the same radiotherapy plus adjuvant chemotherapy with procarbizine, lomustine, and vincristine (PCV; lomustine 110 mg/m2 on Day 1, procarbazine 60 mg/m2 on Days 8-21, and vincristine 1.4 mg/m2 on Days 8 and 29 every 42 days; Group B; n = 32 patients), or received the same radiotherapy plus adjuvant temozolomide (150 mg/m2 for 5 days every 28 days; Group C; n = 22 patients). RESULTS. The median time to disease progression (TTP) and median survival MST were 7.2 months (95% confidence interval [95%CI], 6.34-8.64) and 12.5 months (95%CI, 11.6-14.8), respectively. The TTP was significantly better for Group C compared with Groups A and B (10.7 months vs. 5.3 months and 6.9 months, respectively; P = 0.0002). Karnofsky performance status (KPS) (P <0.001) and temozolomide (P <0.001) were the only independent prognostic factors. Overall survival was better in Group C compared with Group A (14.9 months vs. 11.2 months; P = 0.002), but there were no statistical differences found between Groups A and B or between Groups B and C. Only KPS (P <0.001) was predictive of overall survival, even if temozolomide chemotherapy was very close to the significance level (P = 0.058). Hematologic Grade 3-4 toxicity was higher with the PCV chemotherapy regimen compared with the temozolomide chemotherapy regimen. CONCLUSIONS. Age alone should not preclude appropriate treatment in elderly patients with good performance status, for whom definitive radiation therapy and adjuvant chemotherapy with temozolomide is advised.

AB - BACKGROUND. Elderly patients (age > 65 years) with glioblastoma multiforme frequently are excluded from clinical studies, and prospective trials for patients with this age group do not exist to date. METHODS. The authors conducted a prospective trial in 79 consecutive elderly patients with glioblastoma who underwent surgery and received radiotherapy (59.44 grays in 33 fractions; Group A; n = 24 patients) or received the same radiotherapy plus adjuvant chemotherapy with procarbizine, lomustine, and vincristine (PCV; lomustine 110 mg/m2 on Day 1, procarbazine 60 mg/m2 on Days 8-21, and vincristine 1.4 mg/m2 on Days 8 and 29 every 42 days; Group B; n = 32 patients), or received the same radiotherapy plus adjuvant temozolomide (150 mg/m2 for 5 days every 28 days; Group C; n = 22 patients). RESULTS. The median time to disease progression (TTP) and median survival MST were 7.2 months (95% confidence interval [95%CI], 6.34-8.64) and 12.5 months (95%CI, 11.6-14.8), respectively. The TTP was significantly better for Group C compared with Groups A and B (10.7 months vs. 5.3 months and 6.9 months, respectively; P = 0.0002). Karnofsky performance status (KPS) (P <0.001) and temozolomide (P <0.001) were the only independent prognostic factors. Overall survival was better in Group C compared with Group A (14.9 months vs. 11.2 months; P = 0.002), but there were no statistical differences found between Groups A and B or between Groups B and C. Only KPS (P <0.001) was predictive of overall survival, even if temozolomide chemotherapy was very close to the significance level (P = 0.058). Hematologic Grade 3-4 toxicity was higher with the PCV chemotherapy regimen compared with the temozolomide chemotherapy regimen. CONCLUSIONS. Age alone should not preclude appropriate treatment in elderly patients with good performance status, for whom definitive radiation therapy and adjuvant chemotherapy with temozolomide is advised.

KW - Chemotherapy

KW - Elderly

KW - Glioblastoma

KW - Radiotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=0037303441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037303441&partnerID=8YFLogxK

U2 - 10.1002/cncr.11097

DO - 10.1002/cncr.11097

M3 - Article

C2 - 12548608

AN - SCOPUS:0037303441

VL - 97

SP - 657

EP - 662

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -